Department of Integrative Nursing Care, UTHSC-SON, USA.
Neuro Oncol. 2012 Oct;14(10):1203-14. doi: 10.1093/neuonc/nor223. Epub 2012 Feb 3.
Anti-angiogenic therapies, including bevacizumab, are being used with increasing frequency in the management of malignant glioma. Common clinically significant toxicities include hypertension and proteinuria, poor wound healing, and the potential for thromboembolic events. Literature related to the use of bevacizumab in malignant glioma, reported toxicities in this patient population, and management of these toxicities was reviewed. Recommendations for assessment and management are provided. Anti-angiogenic therapies will continue to have a role in the treatment of malignant glioma. Further studies of the prevention, assessment, and management of these toxicities are warranted.
抗血管生成治疗，包括贝伐珠单抗，在恶性胶质瘤的治疗中越来越频繁地使用。常见的临床意义重大的毒性包括高血压和蛋白尿、伤口愈合不良和血栓栓塞事件的潜在风险。本文复习了与贝伐珠单抗在恶性胶质瘤中的应用相关的文献，报告了该患者人群中的毒性反应以及这些毒性的处理方法。提供了评估和管理的建议。抗血管生成治疗将继续在恶性胶质瘤的治疗中发挥作用。需要进一步研究这些毒性的预防、评估和管理。
